Risk-reducing mastectomy

What the operation is

A risk-reducing mastectomy — sometimes called a prophylactic mastectomy — is the surgical removal of healthy breast tissue to reduce the future risk of developing breast cancer in patients who carry a substantially raised lifetime risk. Almost all are bilateral (both breasts), with immediate reconstruction, and are typically performed using skin-sparing or nipple-sparing technique to preserve as much of the natural appearance as possible.

This is one of the few areas in surgery where a major operation is offered to a patient who, at the time of surgery, is not unwell. That asymmetry — operating on healthy tissue — is taken seriously. A risk-reducing mastectomy is never a routine recommendation; it is a discussion that needs unhurried time, full information, and clear understanding of the alternatives.

Who it is offered to

Risk-reducing mastectomy is considered for patients whose lifetime risk of breast cancer is sufficiently high that the operation offers a meaningful reduction over surveillance alone. The most common groups are:

BRCA1 carriers — cumulative breast cancer risk to age 80 of around 70–80% (estimates vary by study and family).
BRCA2 carriers — cumulative risk to age 80 of around 65–80%.
PALB2 carriers — lifetime risk approximately 35–55%, varying with family history (Yang et al., 2020).
TP53 (Li-Fraumeni) carriers — substantially raised risk, often presenting at younger ages.
Other moderate-penetrance gene carriers — for example CHEK2 or ATM — where the gene mutation combines with a strong family history to push the formally assessed lifetime risk into the high-risk category (≥30%). Risk-reducing mastectomy is not routinely offered for a moderate-risk gene alone.
Patients with a very strong family history (typically multiple first- and second-degree relatives with early breast and/or ovarian cancer) but no identified gene, where formal risk assessment puts the lifetime risk at over ~30%.

Risk-reducing mastectomy after a previous breast cancer in the other breast is a separate situation — sometimes called a contralateral risk-reducing mastectomy — and is discussed where the index cancer treatment pathway leaves the contralateral breast at meaningful future risk.

How much does it reduce the risk?

The figures are well established for BRCA carriers and consistent across major studies:

Bilateral risk-reducing mastectomy reduces breast cancer risk by approximately 90–95% in BRCA1 and BRCA2 carriers (Heemskerk-Gerritsen et al., 2019). In absolute terms this means a residual lifetime risk of roughly 2–5%.
The residual risk reflects the small amount of breast tissue that cannot safely be removed without compromising the skin envelope or the chest wall, leaving a residual lifetime risk of roughly 2–5% in BRCA carriers.
Risk reduction does not translate one-for-one into mortality reduction, because surveillance also catches many cancers at curable stages. The all-cause mortality benefit is real but smaller than the cancer-incidence reduction. This is part of the consultation discussion.

For patients with a moderate-penetrance mutation (PALB2, CHEK2, ATM) or family-history-based high risk, the absolute risk reduction is proportionally less because the starting risk is lower — but the relative reduction (~90–95%) is similar.

The alternatives — these are real options

Risk-reducing mastectomy is one of three reasonable approaches for high-risk patients. The others are:

Enhanced surveillance

For high-risk patients, the NHS and most private pathways offer annual breast MRI surveillance — typically from age 30 for BRCA1 and BRCA2 carriers, and from age 20 for TP53 (Li-Fraumeni) carriers under NICE guidance. Annual mammography is usually added from age 40 for BRCA carriers; mammography is generally avoided under 30 in TP53 because of radiation sensitivity. The aim is to catch any cancer that does develop at the earliest, most curable stage. Surveillance does not prevent cancer; it detects it early.

Chemoprevention

Tamoxifen (typically for 5 years, in pre-menopausal patients) and NICE recommends three options for chemoprevention in the UK: tamoxifen for 5 years (typically pre-menopausal), anastrozole for 5 years (post-menopausal, first-line for high risk), or raloxifene for 5 years (post-menopausal women with a uterus, where tamoxifen/anastrozole are unsuitable). Across trials these reduce breast cancer incidence by roughly 30–50% in high-risk women. They have side-effects — hot flushes, joint aches, a small increased risk of thrombosis with tamoxifen — and the decision is individual. Chemoprevention can be combined with surveillance, and sometimes with a delayed surgical option.

Continuing as you are

For some patients, the right answer at this point in life is to continue with regular surveillance, addressing surgical risk reduction as a question to revisit later. There is no clinical pressure to act before you have weighed the options properly.

How the decision is made

The decision-making process follows a structured pathway:

Genetic testing and counselling — under the care of a clinical geneticist, who explains the implications of the result, the options for at-risk relatives, and the recommended surveillance schedule. Most patients seen for surgical consideration have already been through this process; for those who haven’t, referral is arranged.
Family history verification — where no genetic mutation has been identified, NICE CG164 requires that the family history is verified (medical records, death certificates) before bilateral risk-reducing mastectomy is offered; this is arranged through the genetics service.
Risk assessment — a formal estimate of lifetime breast cancer risk, taking into account the gene (where identified), family history, and personal risk factors.
Surgical consultation — a long appointment to discuss the operation in detail: what is removed, what is preserved, the reconstructive options, the recovery, the residual risk, and the realistic expectations for cosmetic outcome and sensation.
Reconstructive consultation — discussion of implant-based versus autologous (DIEP) reconstruction, immediate versus delayed, and whether nipple-sparing technique is suitable. For DIEP reconstruction, a joint consultation with a plastic-surgery colleague is arranged.
Time to decide — most patients take several weeks to months between consultation and surgery. There is no need to rush. Many patients have a second consultation before booking.
Multidisciplinary review — the operation is discussed at an MDT meeting before booking, the same standard that applies to cancer cases.

What the operation involves

Anaesthetic: general anaesthetic.
Length of operation: typically 4–5 hours for bilateral mastectomy with implant-based reconstruction; 8–10 hours for bilateral mastectomy with bilateral DIEP reconstruction.
Hospital stay: 1–2 nights for implant-based reconstruction; 4–5 nights for DIEP.
Sentinel lymph node biopsy is not performed in risk-reducing mastectomy, because there is no diagnosed cancer to drain. (If unexpected cancer is found in the mastectomy specimen — which is uncommon but does happen — sentinel biopsy may be done at a second operation if the cancer characteristics warrant it.)
Drains: 1–2 surgical drains per side, typically removed in the first 1–2 weeks.

Nipple-sparing versus skin-sparing

For risk-reducing mastectomy, nipple-sparing technique is preferred where the anatomy allows it — preserving both the skin envelope and the nipple-areolar complex gives the most natural-looking outcome, particularly important when there is no cancer in the breast.

Nipple-sparing is suitable when:

The breasts are not very large or very ptotic (drooping) — these can compromise blood supply to the nipple.
The patient does not smoke, or can stop for a window around the surgery.
The surgical team is experienced with the technique and the immediate-reconstruction pathway.

Where nipple-sparing is not suitable, skin-sparing mastectomy preserves the breast skin envelope but removes the nipple, with reconstruction filling the envelope. Nipple reconstruction can be offered later if wanted, typically as a small day-case procedure 6–12 months after the original operation.

Recovery

First two weeks — at home with drains in place. Limited arm movement on both sides. Simple pain relief; some patients use moderate pain relief in the first week. The bilateral nature of the operation makes everyday tasks (dressing, washing) more dependent on help in the first 1–2 weeks.
Weeks 2–6 — progressive shoulder mobilisation with physiotherapy, drains usually out, return to driving around 3–4 weeks. Most patients with desk-based work return at 4–6 weeks.
Three months — most physical activity resumed for implant-based reconstruction. DIEP needs an additional month or two for full abdominal recovery.
One year — most patients consider themselves “back to normal”, with the reconstructed breasts having settled into their final shape.

Most patients need a revision operation at 6–12 months for symmetry, scar refinement, or — where the nipple was not preserved — nipple reconstruction. This is part of the usual arc rather than a sign of a problem.

What is preserved, and what is not

Honesty about outcomes is important — and what to expect after risk-reducing mastectomy is different from what a patient may imagine before surgery.

Sensation in the chest wall is significantly reduced. Even when the nipple is preserved, sensation in the nipple is usually reduced and sometimes absent. Some sensation may return over months to years, but full pre-operative sensation typically does not.
Breastfeeding is no longer possible after risk-reducing mastectomy, so timing relative to family planning is part of the discussion for younger patients.
The reconstructed breasts are not functional breasts in the way the original tissue was; they are a reconstruction of the appearance.
The cosmetic result is usually good, particularly with experienced bilateral surgery, but is not identical to the natural breasts. Photographs of the range of outcomes are shown at consultation.

These are not reasons to avoid the operation — for many patients, risk reduction is the priority and the trade-offs are acceptable. They are reasons to make the decision with full information.

The ovarian-cancer conversation

For BRCA1, BRCA2, and PALB2 carriers, ovarian cancer risk is also raised, and risk-reducing salpingo-oophorectomy (removal of the fallopian tubes and ovaries) is usually recommended in the late 30s for BRCA1 and the early 40s for BRCA2. This is performed by a gynaecological surgeon, not at the breast practice, but it is part of the broader risk-management plan and is coordinated with the genetics team.

The two operations are usually planned separately — most patients do not have them on the same day — and the timing is individual.

Common questions The questions patients ask first

At what age should risk-reducing mastectomy be considered?

There is no fixed age. Many BRCA1 carriers consider surgery in their late 20s to mid-30s, BRCA2 carriers a few years later. The decision balances the rising lifetime risk (which accelerates from the mid-30s for BRCA1) against family-planning considerations, life circumstances, and personal readiness. Some patients have surgery in their 40s or 50s having spent earlier years on surveillance.

Can I have surgery on one breast first and the other later?

Bilateral risk-reducing mastectomy is the standard, because the risk is bilateral. Staged unilateral surgery is occasionally chosen by patients who want to test the recovery and the cosmetic result before committing to the second side. It is a reasonable choice but introduces a period of asymmetry between the operations.

Will my insurance cover it?

Most UK private medical insurers cover risk-reducing mastectomy and reconstruction when there is a confirmed high-risk genetic mutation or a formally documented very-high-risk family history. Pre-authorisation requires the genetic test result or the risk-assessment documentation. The PA will help you liaise with your insurer.

What if cancer is found in the mastectomy specimen?

This happens in a small percentage of risk-reducing mastectomies — typically a small, early cancer that imaging had not detected. It is the reason every specimen is examined in detail by a pathologist. If cancer is found, the case is reviewed at MDT and a decision is made about whether any additional treatment (sentinel lymph node biopsy, hormone therapy, or rarely chemotherapy) is needed. The reconstruction is not affected.

Is there a second operation later for the implants?

Implant reconstructions are not lifetime devices and most patients will need a revision or exchange at some point — often after 10-15 years, sometimes earlier. Long-term implant care includes awareness of late changes such as seroma; this is covered in detail at the Implant-based reconstruction consultation. DIEP reconstructions usually do not need revision over the longer term. DIEP reconstructions usually do not need revision over the longer term. This is part of the choice between implant-based and autologous reconstruction.

Can I change my mind partway through?

Yes. The decision is yours and remains yours throughout. Patients sometimes book surgery and then defer it, or proceed with one side and pause before the second, or decide on surveillance after a consultation. There is no clinical pressure to a particular decision; the role of the consultation is to make sure the decision is informed.